Please use this identifier to cite or link to this item:
|Title:||Assessment and management of male androgen disorders: an update.|
|Authors:||Chan, Irene;Fui, Mark Ng Tang;Zajac, Jeffrey D;Grossmann, Mathis|
|Affiliation:||MBBS, BMedSc, Endocrinology Advanced Trainee, Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australia.|
|Citation:||Australian Family Physician; 43(5): 277-82|
|Abstract:||Male hypogonadism, caused by intrinsic pathology of the hypothalamic-pituitary-testicular (HPT) axis, is an under-diagnosed condition not to be missed. By contrast, late onset hypogonadism (LOH), due to functional suppression of the HPT axis from age-related comorbidities, may be less common than previously believed.This article outlines the aetiology, clinical features, investigation and management of male hypogonadism and discusses the more controversial area of LOH.Pathologically based hypogonadism is, after a thorough diagnostic work-up, treated with testosterone replacement therapy, unless fertility is desired. LOH with modest reductions in testosterone levels should primarily be managed by attention to lifestyle measures, especially weight loss, and optimisation of comorbidities. Clear treatment goals should be identified, and efficacy and safety should be monitored according to published clinical practice guidelines.|
|Internal ID Number:||24791767|
|Subjects:||Age of Onset|
Androgens.adverse effects.therapeutic use
Hormone Replacement Therapy.adverse effects
Testosterone.adverse effects.therapeutic use
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.